Mirai Genomics Receives CE Mark for GenPad Diagnostic Solution

May 24, 2022

Mirai Genomics is happy to announce that the GenPad Diagnostic Solution (GenPad Analyzer and Test Kit for SARS-CoV-2 RNA Detection in Biological Material Using PCR Method) received the CE mark on May 24, 2022, bringing reliable COVID-19 testing and clearing it for sale and distribution in the European Union (EU).

Project Free COVID-19 PCR testing for Tokyo residents
SmartAmp Station at Tokyo Dome City

February 16, 2022

The second SmartAmp PCR test laboratory was opened at Tokyo Dome City on February, 14.

Tokyo residents can get a free COVID test at SmartAmp Station till 6 March (depending on period set by Tokyo Metropolitan Government).

Mirai Genomics Takes Part in MEDICA 2021

November 18, 2021

On November 15-18, 2021, Mirai Genomics took part in the world forum MEDICA 2021 presenting its diagnostic solutions.

MEDICA is the leading international trade fair in the world, attracting more than 5,600 exhibitors and 120,000 visitors from over 66 countries each year.

In the last 40 years, Medica has been expanding its horizons, and every year the whole healthcare industry gathers together to meet international experts and market leaders.

Comparing in Nikkan. A New Device, New Opportunities

November 4, 2021

The Nikkan article provides information on several diagnostic devices. GenPad gives the best result in terms of sensitivity and at the same time has the advantage of portability and compactness.

A palm-sized device has been designed for on-the-spot COVID-19 testing. Based on the PCR SmartAmp technology, it offers high level of sensitivity and specificity. It also allows for building up a cluster of up to 96 devices connected to one PC.

See more here.

Yomiuri Shimbun Publication

October 29, 2021

The Yomiuri Shimbun, one of the five national newspapers in Japan, published an article about GenPad. On October 28, 2021, GenPad was presented to the general public in Japan as a small-sized device able to test COVID-19 in just 40 minutes.

The device size is 11 cm in height, 12 cm in length, and 4 cm in width. The cartridge with the collected saliva sample is inserted into the device and the results are ready in 40 minutes.

Until now, during the analysis, samples with saliva were transported to a special institution where additional devices are located. When using GenPad, this is not required anymore.

On November 6, GenPad was tested with Japanese Fencing Federation athletes on the eve of a fencing tournament throughout Japan.

See more here.

Kanagawa Prefecture press conference announces technologies of Mirai Genomics

On June 28, 2021, Kanagawa Prefecture governor Yuji Kuroiwa held a press conference announcing two COVID-19 technologies that have been collaboratively developed by Mirai Genomics and Kanagawa Prefecture.

The first technology is PEM reagents, reagents able to identify simultaneously the infection presence and the SARS-CoV-2 mutant strains by PCR method.

The second technology is GenPad, a cutting-edge POC solution, with 1 step to get the result with 99.9% accuracy in 40 minutes using own licensed SmartAmp® PCR technology.

Kanagawa Prefecture will continue to support these technologies that greatly contribute to the prevention of the infection spread in the prefecture.

Mirai Genomics takes part in the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

On July 10, 2021 Mirai Genomics took part in the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). ECCMID is one of the most comprehensive and influential congresses in the field and brings together more than 14,000 colleagues from all over the world.

The session of Mirai Genomics hosted Prof. Hayashizaki, CEO of Mirai Genomics and a well-established scientist known worldwide as a leading specialist in genome research and covered the best practices use for COVID-19 testing, underlining GenPad as a POC diagnostic method with a superior testing accuracy.

You could watch the full version of the session here.